Rechberger, J.S.; Porath, K.A.; Zhang, L.; Nesvick, C.L.; Schrecengost, R.S.; Sarkaria, J.N.; Daniels, D.J.
IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma. Pharmaceutics 2022, 14, 922.
https://doi.org/10.3390/pharmaceutics14050922
AMA Style
Rechberger JS, Porath KA, Zhang L, Nesvick CL, Schrecengost RS, Sarkaria JN, Daniels DJ.
IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma. Pharmaceutics. 2022; 14(5):922.
https://doi.org/10.3390/pharmaceutics14050922
Chicago/Turabian Style
Rechberger, Julian S., Kendra A. Porath, Liang Zhang, Cody L. Nesvick, Randy S. Schrecengost, Jann N. Sarkaria, and David J. Daniels.
2022. "IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma" Pharmaceutics 14, no. 5: 922.
https://doi.org/10.3390/pharmaceutics14050922
APA Style
Rechberger, J. S., Porath, K. A., Zhang, L., Nesvick, C. L., Schrecengost, R. S., Sarkaria, J. N., & Daniels, D. J.
(2022). IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma. Pharmaceutics, 14(5), 922.
https://doi.org/10.3390/pharmaceutics14050922